YANK!
YOUTUBE19MOCT 6, 2026

Peptides Are Insane

Jeff Nippard

A biochemist-turned-fitness-creator runs the clinical tape on GLP-1s, BPC-157, and anti-aging peptides — separating the one category with real human evidence from two that are mostly hype.

View video chapters →Jump to any chapter, and yank the one you came for.

View source

AI summary

Generated by Yank from this source. A summary, not quoted language.

جيف نيبارد، حاصل على شهادة في الكيمياء الحيوية، يستعرض في هذا الفيديو عالم الببتيدات التي باتت منتشرة على وسائل التواصل الاجتماعي، مصنّفاً إياها في ثلاث فئات رئيسية: ببتيدات فقدان الدهون، وببتيدات التئام الإصابات، وببتيدات مكافحة الشيخوخة. يوضح أن الببتيدات من الناحية الكيميائية أقرب إلى البروتين، وهي سلاسل قصيرة من الأحماض الأمينية، وليست منشطات ولا منبهات.

Yank summary

What matters, in Yank’s words, each linked to where the source says it.

  1. واحد من كل ثمانية بالغين في الولايات المتحدة يقول إنه يستخدم ببتيدات فقدان الدهون، وعشرات الملايين يتناولونها حول العالم.

  2. في تجربة سريرية، خسر متناولو سيماجلوتيد 34 رطلاً في 16 شهراً مقابل 6 أرطال فقط لمجموعة الدواء الوهمي.

  3. بدون رفع الأثقال وتناول البروتين الكافي، فإن حوالي 40% من الوزن المفقود عند استخدام ببتيد GLP-1 يكون كتلة عضلية.

  4. BPC-157 لم يُدرس رسمياً إلا على 30 شخصاً فقط، مقارنةً بعشرات الآلاف في تجارب سيماجلوتيد وتيرزيباتيد.

  5. الإفراط في تنشيط إنزيم التيلوميراز الذي يستهدفه إيبتالون قد يُشارك في تطور السرطان، وفق ما يشير إليه الفيديو.

Yank’s 5

May find some of the same lines.
1 of 5

Without weight training and adequate protein, about 40% of weight lost on a GLP-1 peptide is muscle mass — almost certainly not from the peptide itself, but from people losing weight without eating enough protein or training hard enough.

Speaker not established[8:22]
Why Yank kept it

Muscle loss blamed on users' habits, not the peptide, reframing a common criticism of GLP-1 drugs.

2 of 5

BPC-157, the 'wolverine peptide' all over the internet, has been formally studied in only 30 people. That's it. Semaglutide was tested on tens of thousands across placebo-controlled Phase III trials.

Speaker not established[12:48]
Why Yank kept it

The evidence gap between BPC-157 hype and semaglutide's rigorous trials exposes how unevenly the peptide landscape is researched.

3 of 5

The group that took semaglutide lost 34 pounds in 16 months. The group that took the placebo lost 6. The only difference was one peptide.

Speaker not established[4:45]
Why Yank kept it

A stark before-and-after comparison isolates semaglutide as the sole variable driving a nearly sixfold difference in fat loss.

4 of 5

Obesity has biological drivers we can't necessarily overcome with discipline or willpower alone — these drugs target receptors in the brain to override those biological drivers. They level the playing field.

Speaker not established[9:50]
Why Yank kept it

Reframes obesity as a biology problem, not a character flaw, justifying why pharmacological intervention is legitimate rather than a shortcut.

5 of 5

Over-activating telomerase may be involved in cancer development. So it's a delicate balance.

Speaker not established[16:36]
Why Yank kept it

Potential cancer risk from telomerase upregulation signals why peptide optimization cannot simply chase one benefit without consequence.

Ask this source

Ask about anything in this video. Yank answers only from what the source says, shows you where, and tells you when the source doesn’t say.

Answers are written by Yank from the source, for you. Nothing you ask is saved or published.